276 related articles for article (PubMed ID: 18806775)
1. Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy.
Wang Z; Smith KS; Murphy M; Piloto O; Somervaille TC; Cleary ML
Nature; 2008 Oct; 455(7217):1205-9. PubMed ID: 18806775
[TBL] [Abstract][Full Text] [Related]
2. Transcriptional activation of the mixed lineage leukemia-p27Kip1 pathway by a somatostatin analogue.
Horiguchi K; Yamada M; Satoh T; Hashimoto K; Hirato J; Tosaka M; Yamada S; Mori M
Clin Cancer Res; 2009 Apr; 15(8):2620-9. PubMed ID: 19318494
[TBL] [Abstract][Full Text] [Related]
3. A Novel Glycogen Synthase Kinase-3 Inhibitor Optimized for Acute Myeloid Leukemia Differentiation Activity.
Hu S; Ueda M; Stetson L; Ignatz-Hoover J; Moreton S; Chakrabarti A; Xia Z; Karan G; de Lima M; Agrawal MK; Wald DN
Mol Cancer Ther; 2016 Jul; 15(7):1485-1494. PubMed ID: 27196775
[TBL] [Abstract][Full Text] [Related]
4. β-Catenin mediates the establishment and drug resistance of MLL leukemic stem cells.
Yeung J; Esposito MT; Gandillet A; Zeisig BB; Griessinger E; Bonnet D; So CW
Cancer Cell; 2010 Dec; 18(6):606-18. PubMed ID: 21156284
[TBL] [Abstract][Full Text] [Related]
5. MLL-TET1 fusion protein promotes immortalization of myeloid progenitor cells and leukemia development.
Kim HS; Oh SH; Kim JH; Kim JY; Kim DH; Lee SJ; Choi SU; Park KM; Ryoo ZY; Park TS; Lee S
Haematologica; 2017 Nov; 102(11):e434-e437. PubMed ID: 28798069
[No Abstract] [Full Text] [Related]
6. Selective treatment of mixed-lineage leukemia leukemic stem cells through targeting glycogen synthase kinase 3 and the canonical Wnt/β-catenin pathway.
Fung TK; Gandillet A; So CW
Curr Opin Hematol; 2012 Jul; 19(4):280-6. PubMed ID: 22525581
[TBL] [Abstract][Full Text] [Related]
7. GSK-3 as a novel prognostic indicator in leukemia.
Ruvolo PP
Adv Biol Regul; 2017 Aug; 65():26-35. PubMed ID: 28499784
[TBL] [Abstract][Full Text] [Related]
8. Fms-like tyrosine kinase 3 ligand stimulation induces MLL-rearranged leukemia cells into quiescence resistant to antileukemic agents.
Furuichi Y; Goi K; Inukai T; Sato H; Nemoto A; Takahashi K; Akahane K; Hirose K; Honna H; Kuroda I; Zhang X; Kagami K; Hayashi Y; Harigaya K; Nakazawa S; Sugita K
Cancer Res; 2007 Oct; 67(20):9852-61. PubMed ID: 17942916
[TBL] [Abstract][Full Text] [Related]
9. A MENage à Trois in leukemia.
Roudaia L; Speck NA
Cancer Cell; 2008 Jul; 14(1):3-5. PubMed ID: 18598937
[TBL] [Abstract][Full Text] [Related]
10. The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis.
Yokoyama A; Somervaille TC; Smith KS; Rozenblatt-Rosen O; Meyerson M; Cleary ML
Cell; 2005 Oct; 123(2):207-18. PubMed ID: 16239140
[TBL] [Abstract][Full Text] [Related]
11. Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia.
Dafflon C; Craig VJ; Méreau H; Gräsel J; Schacher Engstler B; Hoffman G; Nigsch F; Gaulis S; Barys L; Ito M; Aguadé-Gorgorió J; Bornhauser B; Bourquin JP; Proske A; Stork-Fux C; Murakami M; Sellers WR; Hofmann F; Schwaller J; Tiedt R
Leukemia; 2017 Jun; 31(6):1269-1277. PubMed ID: 27840424
[TBL] [Abstract][Full Text] [Related]
12. Blocked inhibitory serine-phosphorylation of glycogen synthase kinase-3alpha/beta impairs in vivo neural precursor cell proliferation.
Eom TY; Jope RS
Biol Psychiatry; 2009 Sep; 66(5):494-502. PubMed ID: 19520363
[TBL] [Abstract][Full Text] [Related]
13. Glycogen synthase kinase 3 has a limited role in cell cycle regulation of cyclin D1 levels.
Yang K; Guo Y; Stacey WC; Harwalkar J; Fretthold J; Hitomi M; Stacey DW
BMC Cell Biol; 2006 Aug; 7():33. PubMed ID: 16942622
[TBL] [Abstract][Full Text] [Related]
14. Mll fusions generated by Cre-loxP-mediated de novo translocations can induce lineage reassignment in tumorigenesis.
Drynan LF; Pannell R; Forster A; Chan NM; Cano F; Daser A; Rabbitts TH
EMBO J; 2005 Sep; 24(17):3136-46. PubMed ID: 16096649
[TBL] [Abstract][Full Text] [Related]
15. Establishment of a novel childhood acute myeloid leukaemia cell line, KOPM-88, containing partial tandem duplication of the MLL gene and an in vivo model for childhood acute myeloid leukaemia using NOD/SCID mice.
Hayashi M; Kondoh K; Nakata Y; Kinoshita A; Mori T; Takahashi T; Sakamoto MI; Yamada T
Br J Haematol; 2007 May; 137(3):221-32. PubMed ID: 17408461
[TBL] [Abstract][Full Text] [Related]
16. Identification of MLL-fusion/MYC⊣miR-26⊣TET1 signaling circuit in MLL-rearranged leukemia.
Huang H; Jiang X; Wang J; Li Y; Song CX; Chen P; Li S; Gurbuxani S; Arnovitz S; Wang Y; Weng H; Neilly MB; He C; Li Z; Chen J
Cancer Lett; 2016 Mar; 372(2):157-65. PubMed ID: 26791235
[TBL] [Abstract][Full Text] [Related]
17. The MLL fusion gene, MLL-AF4, regulates cyclin-dependent kinase inhibitor CDKN1B (p27kip1) expression.
Xia ZB; Popovic R; Chen J; Theisler C; Stuart T; Santillan DA; Erfurth F; Diaz MO; Zeleznik-Le NJ
Proc Natl Acad Sci U S A; 2005 Sep; 102(39):14028-33. PubMed ID: 16169901
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia.
Feng Z; Yao Y; Zhou C; Chen F; Wu F; Wei L; Liu W; Dong S; Redell M; Mo Q; Song Y
J Hematol Oncol; 2016 Mar; 9():24. PubMed ID: 26970896
[TBL] [Abstract][Full Text] [Related]
19. Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors.
Milne TA; Hughes CM; Lloyd R; Yang Z; Rozenblatt-Rosen O; Dou Y; Schnepp RW; Krankel C; Livolsi VA; Gibbs D; Hua X; Roeder RG; Meyerson M; Hess JL
Proc Natl Acad Sci U S A; 2005 Jan; 102(3):749-54. PubMed ID: 15640349
[TBL] [Abstract][Full Text] [Related]
20. Targeting glycogen synthase kinase 3 for therapeutic benefit in lymphoma.
Wu X; Stenson M; Abeykoon J; Nowakowski K; Zhang L; Lawson J; Wellik L; Li Y; Krull J; Wenzl K; Novak AJ; Ansell SM; Bishop GA; Billadeau DD; Peng KW; Giles F; Schmitt DM; Witzig TE
Blood; 2019 Jul; 134(4):363-373. PubMed ID: 31101621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
